Short answer
AVITA Medical, Inc. (RCEL) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). $500,000 fee secures first-offer and refusal rights for potential EU, U.K., and Australian territory expansion.
AVITA Medical, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $500,000 fee secures first-offer and refusal rights for potential EU, U.K., and Australian territory expansion
- AVITA’s PermeaDerm revenue share rises to 67% for sheets and 80% for gloves
- 2026 revenue-sharing payments must reach $1.0 million, with 20% annual minimum growth through 2030
- Prior minimum payment requirements waived, reducing legacy commitment risk
- Stedical gains select U.S. commercialization rights, while AVITA supplies products at cost-plus pricing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AVITA Medical, Inc. 8-K filings
Get the next RCEL 8-K as it lands
Follow RCEL for push alerts, or ask the research agent what this filing means.